Sign up to save your podcasts
Or
Share PER Podcast Sessions
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
PER Podcast Sessions
PER Podcast Sessions episodes
- S2 Ep49: Choosing Appropriate Covid-19 Prevention Strategies
Charles Vega, MD, FAAFP
Clinical Professor, Department of Family Medicine
UC Irvine School of Medicine
Santa Ana, CADisclosures: Advisor, Consultant, Fee for Service Recipient: Boehringer Ingelheim, Exact Sciences, GSK
Stefan Gravenstein, MD, MPH
Professor of Medicine
Brown University
Providence, RIDisclosures: Advisor, Consultant, Fee For Service Recipient: AstraZeneca, Genentech, GSK, Moderna, Pfizer, Sanofi; Speakers Bureau: Moderna, Sanofi; Grant/Research Funding: Genentech, GSK, Moderna, Pfizer, Sanofi
Elie Saade, MD, MPH
Associate Professor of Medicine
Medical Director, UH Infection Control
Case Western Reserve University
Cleveland, OhioDisclosures: Grant/Research Funding: Johnson & Johnson, Pfizer, Shionogi
Activity Overview
COVID-19 remains a significant challenge for health care systems, contributing to lengthy hospitalizations, long-term health complications, and costly economic burdens. High-risk populations remain vulnerable to severe disease outcomes, with prevention remaining a key component of management. This CME-certified Medical Crossfire® podcast is the second in a 3-part series titled Primary Care Playbook Podcast: Advancing COVID-19 Prophylaxis in Community Practice. In this activity, 3 expert faculty in Family Medicine, Geriatric Medicine, and Infectious Disease exchange unique perspectives and discuss practical approaches to choosing appropriate COVID-19 prevention strategies in clinical practice, including pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), individualized patient selection, and shared decision-making for patients at high risk of severe disease.
FDA Approves Ensitrelvir for Postexposure Prophylaxis of COVID-19
On June 1, 2026, the U.S. Food and Drug Administration has approved ensitrelvir for postexposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with active COVID-19. The approval marks the first oral antiviral option in the United States indicated to help prevent COVID-19 after a known exposure.Ensitrelvir is a SARS-CoV-2 main protease inhibitor administered as a 5-day oral regimen. Its approval was supported by results from the Phase 3 SCORPIO-PEP trial, in which ensitrelvir reduced the risk of symptomatic COVID-19 by 67% compared with placebo through Day 10 in exposed, uninfected individuals.
Target Audience
This educational activity is intended for primary care physicians (PCPs), infectious disease (ID) specialists, critical care physicians, hospitalists, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the treatment of COVID-19.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Describe unmet needs in the prevention and management of COVID-19.
- Assess emerging clinical trial evidence informing the use of current and investigational therapies for the prevention of COVID-19.
- Implement individualized strategies for patients at risk of COVID-19 tailored to disease severity and patient-specific factors.
58 min - S1 Ep1: Emerging Strategies for Covid-19 Prevention and Management
Activity Overview
COVID-19 remains a significant challenge for healthcare systems, contributing to hospitalizations, long-term health complications, and economic burdens. Prevention remains a key component of management, with strategies such as PrEP, PEP, and early therapeutic intervention playing a critical role in reducing transmission, preventing severe illness, and minimizing long-term complications. However, high-risk populations, such as those with obesity, diabetes, cardiovascular disease, chronic lung diseases, chronic kidney disease, and immunocompromising conditions, remain vulnerable to severe disease outcomes.
FDA Approves Ensitrelvir for Postexposure Prophylaxis of COVID-19On June 1, 2026, the U.S. Food and Drug Administration has approved ensitrelvir for postexposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with active COVID-19. The approval marks the first oral antiviral option in the United States indicated to help prevent COVID-19 after a known exposure.
Ensitrelvir is a SARS-CoV-2 main protease inhibitor administered as a 5-day oral regimen. Its approval was supported by results from the Phase 3 SCORPIO-PEP trial, in which ensitrelvir reduced the risk of symptomatic COVID-19 by 67% compared with placebo through Day 10 in exposed, uninfected individuals.
Target AudienceThis educational activity is intended for primary care physicians (PCPs), infectious disease (ID) specialists, critical care and emergency medicine physicians, hospitalists, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the treatment of COVID-19.
Learning ObjectivesUpon successful completion of this activity, you should be better prepared to:
- Summarize unmet needs in the prevention and management of COVID-19.
- Analyze emerging clinical trial evidence informing the use of current and investigational therapies for the prevention and management of COVID-19.
37 min - S2 Ep48: Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; and Matthew P. Goetz, MD, discuss innovations in targeting TROP2 in triple-negative breast cancer treatment.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Evaluate efficacy and safety data from clinical trials evaluating TROP-2–targeted antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC)
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit- Listen to this podcast in its entirety.
- Go to https://www.gotoper.com/credit and enter code: 2342
- Answer the evaluation questions.
- Request credit using the drop-down menu.
You may immediately download your certificate.
Chair
Joyce O’Shaughnessy
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, GSK, Genentech, Genzyme, Gilead Sciences, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily
Faculty
Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Mayo Clinic
Rochester, MN
Disclosures: Consulting fees: AstraZeneca, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, BeiGene USA, Biotheranostics, Biotheryx, eChinaHealth, EcoR1, Eli Lilly & Co, Engage Health Media, Genentech, Incyclix, Laekna, Lilly, Novartis, RNA Diagnostics, Seattle Genetics, Sermonix, Stemline Therapeutics, TerSera Therapeutics; Grant funding: AstraZeneca, ATOSSA Therapeutics, Biotheryx, Lilly, Loxo, Pfizer, Sermonix, SimBioSys; Travel support: Lilly; CME activities: AXIS, BroadcastMed, DAVA Oncology, IDEOlogy Health, MJH Life Sciences, PeerView, Physicians’ Education Resource, Research to Practice, Total Health Conferencing
Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Adviser: Ambryx, Chugai, OBI Pharma, Puma; Consultant: Ambryx, Chugai, OBI Pharma, Puma; Researcher: AstraZeneca, Daiichi Sankyo, F. Hoffman-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Mylan, Napo, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Stemline Therapeutics
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
To learn more about this topic, including information on integrating TROP2-targeted ADCs into individualized treatment plans and addressing disparities in care among diverse populations of patients with TNBC, go to https://www.gotoper.com/ibc25trop2tnbc-activityRelease Date
August 28, 2025
Expiration Date
August 28, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.33 min - S2 Ep47: Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer—The Evolving Role of Antibody-Drug ConjugatesThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Hope S. Rugo, MD; and Joyce O’Shaughnessy, MD, discuss pivotal trials of antibody-drug conjugates in HR+/HER2- and triple-negative subtypes of metastatic breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Assess clinical trial evidence for antibody-drug conjugates in the management of HR+/HER2-, HER2+, and triple-negative breast cancer (TNBC)
- Implement effective toxicity management approaches to optimize outcomes and minimize adverse events for patients receiving ADCs and targeted therapies for HR+/HER-, HER+, and TNBC
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Gilead Sciences, Inc and Helsinn.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6824
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Faculty:
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GSK, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily
Hope S. Rugo, MD
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Adviser: Bristol Myers Squibb, Chugai, Mylan, Napo, Sanofi; Grant/Research Support: Ambrx, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Novartis Pharmaceuticals Corporation, OBI Pharma, Pfizer, Stemline Therapeutics
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on the role of antibody-drug conjugates in metastatic breast cancer, and management of associated adverse events, go to https://www.gotoper.com/annual-oncology-meeting-25-adcs-activity.Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.31 min - S2 Ep46: Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung CancerThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; and Christine M. Lovly, MD, PhD, FASCO, discuss current and emerging treatment strategies targeting HER2 and TROP2 in patients with advanced or metastatic non–small cell lung cancer (NSCLC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Outline current and emerging approaches targeting HER2 in the management of advanced or metastatic NSCLC
- Evaluate emerging evidence and the potential place in the treatment algorithm for novel approaches targeting TROP2 in advanced or metastatic NSCLC
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 2238
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Benjamin P. Levy, MD
Associate Professor
Johns Hopkins School of Medicine
Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center
Sibley Memorial Hospital
Washington, DC
Disclosures: Consultant; Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Eli Lilly, Genentech, Gilead Sciences, Janssen, Merck & Co, Novartis, Takeda.
Faculty:
Ticiana Leal, MD
Associate Professor
Department of Hematology & Oncology
Director, Thoracic Medical Oncology
Medical Director, Clinical Trials Office
Winship Cancer Institute
Emory University
Atlanta, GA
Disclosures: Adviser/Consultant: AbbVie, Amgen, AstraZeneca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Daiichi Sankyo, Genentech, Gilead Sciences, Jazz, Johnson & Johnson, Novartis, Novacure, Pfizer, Regeneron, Roche, Sanofi, Synthekine, Takeda; DSMB: OncoC4; Research grant (paid to institution): Bayer, Boehringer Ingelheim, Daiichi Sankyo, Mythic, Prelude, Synthekine.
Aaron Lisberg, MD
Assistant Professor of Clinical Medicine
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosures: Advisory Board/Consultant: AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Gilead Sciences, IQVIA, Janssen Oncology, Jazz Pharmaceuticals, Leica Biosystems, Lilly, Molecular Axiom, MorphoSys, Novartis, Novocure, Oncocyte, Pfizer, Regeneron, Sanofi; Employment (Spouse): Boston Scientific; Grant/Research Support: AstraZeneca, Calithera Biosciences, Daiichi Sankyo, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics, Seagen (Pfizer), WindMIL Therapeutics; Stock (Spouse): Boston Scientific.
Christine M. Lovly, MD, PhD, FASCO
Associate Professor of Medicine
Division of Hematology-Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Consultant: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Genentech, Gilead, Guardant, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Taiho, Takeda, Tempus; Honoraria Recipient: AbbVie, Amgen, AnHeart, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Foresight, Foundation Medicine, Genentech, Gilead, Guardant, Immunity Bio, Merck, Nuvation, Onviv, Pfizer, Regeneron, Summit, Taiho, Takeda, Tempus.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on biomarker testing in NSCLC, and additional information about HER2-targeted and TROP2-targeted therapy, go https://www.gotoper.com/annual-oncology-meeting-25-her2trop2-activity.Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.35 min - S2 Ep45: Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Vinay Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen Bagley, MD, MSCE; and Angela Waanders, MD, MPH, MS; discuss advancements in targeted therapies to treat adult and pediatric low- and high-grade gliomas.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Integrate recent classification criteria and diagnostic strategies for identification of adult and pediatric patients with glioma
- Incorporate genetic and molecular information to accurately classify gliomas and develop personalized treatment plans
- Appraise recent developments in targeted, immunotherapeutic, and other novel therapeutic approaches, including potential implications of investigational approaches in the care of patients with gliomas
- Determine strategies to integrate targeted and immunotherapeutic approaches and assess the potential implications of emerging novel approaches in the management of pediatric gliomas
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Chimerix, Inc; Day One Biopharmaceuticals; and Servier Pharmaceuticals LLC.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6432
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals; Honorarium: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals
Faculty:
Manmeet Ahluwalia, MD, MBA
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer and Deputy Director
Miami Cancer Institute, Baptist Health South Florida
Miami, FL
Disclosures: Consultant: AnHeart Therapeutics, Apollomics, Bayer, Menarini Ricerche, TherAguix, Varian Medical Systems, ViewRay, Xoft
Stephen J. Bagley, MD, MSCE
Assistant Professor of Medicine and Neurosurgery
Section Chief
Neuro-Oncology Section
Division of Hematology/Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Disclosures: Advisor: Modifi Bio, Servier, Telix; Researcher: GSK, Incyte, Kite (a Gilead company), Lilly, Novocure
Angela Waanders, MD, MPH, MS
Associate Professor of Pediatrics (Hematology, Oncology, and Stem Cell Transplantation)
Section Head, Neuro-Oncology
Director, Precision Medicine Oncology
Gus Foundation Chair in Neuro-Oncology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Ad Hoc Consultant: Day One, Ipsen; Chair: Alexion; Member: Day One; Scientific Advisory Board: Alexion, Day One; Selumetinib Registry: Alexion
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on advancements in targeted therapy in adult and pediatric high- and low-grade gliomas, go https://www.gotoper.com/annual-oncology-meeting-25-glioma-activity.Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.31 min - S2 Ep43: GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerThanks for your interest in this podcast. Please read this important program information before listening.Episode Description
In this podcast, experts Drs Stacey Cohen, Aparna Parikh, Kanwal Raghav, and John Strickler discuss advancements in targeted therapies to treat adult metastatic colorectal cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Define key biomarkers that guide personalized treatment decision-making in patients with metastatic colorectal cancer (mCRC), incorporating multidisciplinary team support
- Apply the latest data on current and emerging treatment options for mCRC, including targeted therapies (eg, BRAF, HER2, KRAS), into clinical practice for optimal patient outcomes
- Identify strategies for monitoring and managing adverse effects of current and emerging therapies for mCRC to ensure treatment adherence and patient safety
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Pfizer, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 4921
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.Chair:
John H. Strickler, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
Duke University
Durham, NC
Co-Leader, Duke Molecular Tumor Board
Associate Director Clinical Research, GI
Duke Cancer Institute
Durham, NC
Disclosures: Consultant: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, Bristol Myers Squibb, Cytovation, Daiichi Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson & Johnson, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Regeneron, Roche/Genentech, Sanofi, Taiho, Takeda, Triumvira, Xilio Therapeutics; Research: AbbVie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/Genentech.
Faculty:
Stacey A. Cohen, MD
Associate Professor, Division of Hematology/Oncology
University of Washington
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, WA
Disclosures: Consultant: AbbVie, Agenus, DoMore Diagnostics, Exact Sciences, GSK, Guardant, Incyte, Janssen, Merck, Pfizer, Roche; IDMC Member: GSK.
Aparna Parikh, MD
Associate Professor of Medicine
Harvard Medical School
Director, Global Cancer Care Program
Massachusetts General Hospital
Boston, MA
Disclosures: Adviser/Consultant: 3T Biosciences, AbbVie, Adroya Sciences, Amgen, Astra Zeneca, Bristol Myers Squibb, Caris, CareSet, CVS, Delicate, DoMore Diagnostics, Eli Lilly, Exact, Foundation Medicine, GSK, Guardant, Hookipa, Incyte, Kahr, Merck, Mirati, MPM Capital, Natera, Parithera, Pfizer, Phesi, PMV, Regeneron, Scare, Science for America, Seagen, Sirtex, Summit Therapeutics, Takeda, Third Rock Ventures, Value Analytics Labs, Xilio, Zola; Chief Scientist: Reversing Early Recurrence; Fees: Up to Date; Research Funding (to institution): Bristol Myers Squibb, Daiichi Sankyo, Erasca, Genentech, Mirati, Parthenon, PMV Pharmaceuticals, Revolution Medicine, Syndax; Shareholder: C2i Genomics, Cadex, Khora, OneCell, Parithera, XGenomes; Travel Fees: Karkinos Healthcare.Kanwal P.S. Raghav, MBBS, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory board: AstraZeneca, Daiichi Sankyo, Pfizer; Research Funding: AstraZeneca, Daiichi Sankyo.Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on clinical trial data for targeted therapies in mCRC, go to https://www.gotoper.com/annual-oncology-meeting-25-mcrc-activity.Release Date
July 30, 2025
Expiration Date
July 30, 2026
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.32 min - S2 Ep42: Medical Crossfire®: Expert Perspectives on c-MET and MET Targeting in NSCLC—Unveiling the Complexities of MET DysregulationThanks for your interest in this podcast. Please read this important program information before listening.Episode Description
In this podcast, experts Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; and Jeremy Segal, MD, PhD, discuss the emerging data and clinical strategies for targeting c-MET overexpression and MET genomic alterations in non–small cell lung cancer (NSCLC), including the role of novel antibody-drug conjugates (ADCs), such as telisotuzumab vedotin (Teliso-V), combination approaches with EGFR-Tyrosine kinase inhibitors (TKIs), and optimal molecular testing practices for appropriate patient selection.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Identify optimal molecular testing strategies for individual categories of MET dysregulation in patients with NSCLC along the continuum of care.
- Assess safety and efficacy results from clinical trials investigating MET-targeted approaches for the management of patients with advanced NSCLC.
- Analyze ongoing trials and emerging data for novel strategies targeting c-MET overexpression in patients with NSCLC with or without EGFR mutations.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from AbbVie, Inc.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 6732
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.
Chair:
Rebecca Heist, MD, MPH
Professor of Medicine
Harvard Medical School
Thoracic Oncology, MGH Cancer
Massachusetts General Hospital
Boston, MA
Disclosures: Consultant: Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck
Faculty:
Alex A. Adjei, MD, PhD, FACP
Chief, Cancer Institute
Director, Taussig Cancer Center
M. Frank Rudy and Margaret D. Rudy Distinguished Chair in
Translational Cancer Research
Cleveland Clinic
Cleveland, OH
Alex A. Adjei, MD, PhD, FACP, has no relevant financial relationships with ineligible companies.Sandip Patel, MD, FASCO
Professor, Medical Oncology
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Experimental Therapeutics Program
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
University of California San Diego
San Diego, CA
Disclosures: Institutional Research Funding:A2 Bio, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Gilead, Iovance, Merck, Pfizer, Roche/Genentech; Scientific Advisory Board: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Eli Lilly, Genentech, Illumina, Jazz, Merck, Pfizer
Jeremy Segal, MD, PhD
Vice Chair, Genomic Pathology
Professor of Pathology
University of Chicago
Chicago, IL
Disclosures: Adviser: AstraZeneca, Bristol Myers Squibb, OrisDX; Equity Recipient: OrisDX; Honoraria Recipient: AstraZeneca, Bristol Myers Squibb, Roche Diagnostics; Speaker: Roche DiagnosticsFaculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on biomarker-driven management of patients with EGFR-mutated non–small cell lung cancer (NSCLC), go to http://gotoper.com/annual-oncology-meeting-25-cmet-activity.Release Date
July 30, 2025
Expiration Date
July 30, 2026Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.49 min - S2 Ep41: Cases & Conversations™: Transforming AML Care – Precision Strategies, Evolving Therapies, and Clinical InsightsThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; and Amer Zeidan, MBBS, MHS; discuss current best practices and emerging strategies in acute myeloid leukemia (AML) management.Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Assess emerging treatment strategies for AML across frontline and relapsed/refractory settings
- Apply findings from recent clinical trials to optimize AML treatment approaches.
Acknowledgment of Educational Grant Support
This activity is supported by educational grants from Rigel Pharmaceuticals, Inc; Syndax Pharmaceuticals, Inc; and Taiho Oncology, Inc.Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.5 Contact Hours.Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 5232
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.Chair:
Gail J. Roboz, MD
Professor of Medicine
Director, Leukemia Program
Weill Cornell Medicine
The New York Presbyterian Hospital
New York, NY
Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses Pharma, Genoptix GlaxoSmithKline, Geron, GlycoMimetics, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, MorphoSys, NeoGenomics, Novartis, OncoPrecision, OncoVerity, Pfizer, Rigel, Roche, Syndax; Grant/Research Support: Janssen.Faculty:
Hagop Kantarjian, MD
Chair, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consultant: AbbVie, Amgen, Ascentage, Bristol Myers Squibb, Pfizer, Takeda; Grant/Research Support: AbbVie, Amgen, Ascentage, Pfizer, Takeda.Catherine Lai, MD, MPH
Associate Professor
Physician Leader, Leukemia Clinical Research Unit
University of Pennsylvania
Perelman Center for Advanced Medicine
Philadelphia, PA
Disclosures: Advisor: Arcellx, BioAscent, Daiichi Sankyo, Rigel, Servier, Syndax, Taiho Oncology; Consultant: AbbVie, Genentech, Rigel.Amer Zeidan, MBBS, MHS
Professor of Medicine
Director of Hematologic Malignancies
Yale University School of Medicine
Yale Cancer Center
New Haven, CT
Disclosures: Consultant: AbbVie, Agios, Akeso Pharma, ALX Oncology, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chiesi, Daiichi Sankyo, Epizyme, Faron, Genentech, Geron, Gilead, GlycoMimetics, Hikma, Janssen, Karyopharm, Keros, Kura, Kyowa Kirin, Lava Therapeutics, Mendus, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Servier, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, Zentalis; Grant/Research Support: AbbVie, Amgen, Astex, Bristol Myers Squibb, Celgene, Geron, Kura, Novartis, Otsuka, Shattuck Labs, Syros.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on diagnostic workups, treatment sequencing, and proactive management of therapy-related toxicities in personalized care for patients with AML go to https://www.gotoper.com/annual-oncology-meeting-25-aml-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.18 min - S2 Ep37: Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingThanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Eileen O’Reilly, MD, and Brian Wolpin, MD, MPH, discuss current principles for molecular testing and emerging targeted therapy approaches for patients with metastatic pancreatic ductal adenocarcinoma.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:- Assess the role of molecular profiling to identify actionable alterations in patients with advanced pancreatic adenocarcinoma (PDAC)
- Analyze clinical data from key trials evaluating emerging therapeutic agents for metastatic PDAC
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Revolution Medicines.Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Instructions on How to Receive Credit
1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 9235
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.
You may immediately download your certificate.Chair:
Eileen M. O’Reilly, MD
Professor of Medicine
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva; Institutional research support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva.
Faculty:
Brian Wolpin, MD, MPH
Professor of Medicine
Director, Gastrointestinal Cancer Center
Director, Hale Family Center for Pancreatic Cancer Research
Robert T. & Judith B. Hale Chair in Pancreatic Cancer
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consulting/advisory board: Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati/Bristol Myers Squibb (BMS), Revolution Medicines, Tango Therapeutics, Third Rock Ventures; Funding (paid to institution): Agios, Amgen, AstraZeneca, Eli Lilly, Harbinger Health, Novartis, Revolution Medicines.
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on targeted therapy approaches for metastatic PDAC, go to https://www.gotoper.com/annual-oncology-meeting-25-pdac-activity
Release Date
July 30, 2025
Expiration Date
July 30, 2026Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.33 min
About PER Podcast Sessions
From the publisher's feed
Physicians' Education Resource® (PER®) is committed to advancing patient care through professional education. This podcast is a natural extension of PER®'s efforts to provide medical education for…
health care providers to stay up to date with advances in medical care, from diagnosis through treatment, with the ultimate goal of improving patient outcomes. Visit www.gotoper.com for more information.